Scope: Autologous and allogeneic cell therapy development; CAR-T, TCR-T, NK, and other advanced modalities; closed-system manufacturing for process robustness; viral vector supply (AAV, LV, retroviral) integrated under one control strategy; cryopreservation, release assays, and stability programs aligned with regulatory expectations. All delivered under a unified digital QMS (ALCOA+), designed for reproducibility and inspection readiness.

A unified approach to cell therapies and vectors

Cell therapy is more than manipulating a population of cells—it is a marriage of cellular biology and genetic delivery systems. Success requires the seamless integration of both sides: living cells engineered for therapeutic potency, and the viral vectors or editing tools that enable them. At MycoVista, we align these workflows under one spine, treating cells and vectors not as separate streams but as interdependent programs. This synergy simplifies comparability, reduces handoffs, and accelerates readiness for IND, IMPD, or BLA submission.

Why teams run cell therapies here

Cell therapy programs often stall not because of science, but because of fragmentation. A sponsor works with one supplier for patient or donor cell processing, another for viral vector supply, and a third for release analytics, and then spends months reconciling the gaps. This patchwork approach creates risk, slows timelines, and undermines comparability. MycoVista was built to eliminate that friction. We unify the entire value chain under one operational and regulatory framework, allowing cell therapy manufacturing to proceed with speed, control, and confidence.

End-to-end integration. We take ownership from the earliest stages of autologous and allogeneic process development through GMP drug product. That means donor or patient material qualification, upstream activation and expansion, vector transduction, downstream harvest and purification, cryopreservation, and clinical release—all under one harmonized QMS. Because every link is handled in-house, sponsors avoid the bottlenecks and inconsistencies that plague multi-supplier programs.

Viral vector and cell synergy. We build AAV, LV, or retroviral platforms alongside the cellular process itself, not in parallel silos. Transduction parameters are defined with both sides in view, ensuring that multiplicity of infection, dose, and expansion kinetics are aligned to the target product profile. This co-development reduces failure points, strengthens potency data, and accelerates regulatory readiness.

Closed-system operations. Every unit operation is designed with contamination control and operator practicality in mind. Automated tubing sets, expansion units, integrated harvest modules, and aseptic fill–finish platforms reduce open steps and make cell therapy manufacturing reproducible at clinical and commercial scales. By prioritizing closed-system capability, we minimize human error, protect sterility, and enable comparability across batches, patients, and sites.

Cryopreservation as an engineered process. We treat freezing and thawing not as a terminal hold, but as a critical manufacturing operation. Our teams empirically validate cryoprotectant recipes, cooling rates, and thaw curves against potency, viability, and functional assays. Packaging formats—cryovials, infusion bags—are qualified for freeze–thaw stress and container closure integrity. The result is a therapy that reaches the patient with the same functional attributes it had at harvest.

Release and stability analytics. Our analytical suite includes flow cytometry panels, ddPCR/qPCR for vector copy number, residual vector assays, potency aligned to therapeutic mechanism, sterility, endotoxin, and mycoplasma testing. Stability programs are built on real-time and accelerated conditions, mapping viability, potency, and identity over time. This gives sponsors the data backbone needed for INDs, IMPDs, and BLAs that withstand review.

Regulatory execution. We don’t retrofit documentation at the end. Every program is mapped from QTPP to CQA to CPP before development begins, with acceptance windows and comparability protocols prespecified. IND/IMPD/BLA sections are authored directly from validated data and batch records, not from generic templates. That makes filings clear, defensible, and inspection-ready.

Background: challenges that actually matter. In our experience, most avoidable failures in cell therapy manufacturing can be traced to a handful of themes: patient-to-patient variability in autologous programs, scalability hurdles in allogeneic platforms, vectors without adequate potency or identity characterization, and cryopreservation protocols that erode viability. We solve these problems at their source. Donor and patient material quality is managed as a process parameter. Vector design and release analytics are locked in early. Cryopreservation is validated empirically for stability. Closed-system trains are designed to match real operator workflows and facility layouts, not theoretical diagrams.

Program spine: QTPP → CQAs → CPPs. The foundation of our approach is defining what success looks like in measurable terms, and then linking every control back to that definition.

• QTPP (intended product): Autologous or allogeneic therapy, intended dose, presentation format, potency window, viability post-thaw, residual levels for DNA, proteins, detergents, and vector, sterility and endotoxin thresholds.
• CQAs (measured attributes): Viability before and after cryopreservation, transduction efficiency, expansion kinetics, potency by functional assay, residual vector, sterility, endotoxin, mycoplasma, and stability readouts.
• CPPs (controlled levers): Patient/donor material parameters, vector dose and MOI, activation and expansion conditions, feed regimes, transduction windows, cryopreservation recipe, fill–finish operations, and closed-system setpoints.

This spine ensures that what we promise in filings can be demonstrated in the plant. It transforms development from a research exercise into an engineered, reproducible system.

In short, MycoVista’s value is not just that we offer every service under one roof. It’s that we connect them into a coherent, data-driven framework that makes cell therapy manufacturing predictable, reproducible, and defensible at every scale. That is why teams bring their programs here—and why they stay.

Background: Challenges that actually matter

The obstacles that derail most cell therapy programs are not mysteries—they’re patterns we see repeated across the industry. Too often, these challenges are only recognized after costly clinical delays. At MycoVista, we address them head-on at program inception, embedding controls into development so avoidable failures never make it to GMP.

Autologous variability. Patient-derived material introduces inevitable heterogeneity. Donor age, disease state, and immune history directly affect viability, expansion kinetics, and transduction efficiency. In many facilities, this variability is treated as “noise” to be managed later. We treat it as a primary process parameter. Incoming acceptance criteria are defined upfront, including viability thresholds, CD3+ percentages, and contamination screens. Material that doesn’t meet criteria is flagged early, saving time, cost, and clinical risk.

Allogeneic scalability. The promise of allogeneic therapies is supply at commercial scale, but that promise collapses if the process train cannot handle bank-to-bank variation or expansion bottlenecks. Many CDMOs underestimate the challenges of industrializing allogeneic workflows. At MycoVista, we engineer scalability from day one—building master and working cell bank strategies, defining expansion envelopes with closed-system bioreactors, and qualifying media/feed regimens to support consistent batch sizes.

Vectors as limiting reagents. In CAR-T, TCR-T, and NK cell therapies, the viral vector is not a side note—it is the payload that defines potency. Programs fail when vectors are not characterized sufficiently to link MOI to clinical dose. We prevent this by integrating vector and cell workflows. Vector genomes, capsid integrity, and infectivity are quantified with orthogonal methods. Release specifications are linked directly to transduction efficiency and potency in the cell process itself. That alignment transforms the vector from a procurement risk into a controlled process variable.

Cryopreservation gaps. A therapy that loses 20% of its potency in distribution isn’t a therapy—it’s a liability. Many sponsors still treat freezing and thawing as procedural steps, not engineered operations. We take the opposite view. Cryopreservation recipes are designed empirically, with cryoprotectant concentration, cooling rate, thaw speed, and container format treated as CPPs. Real-time and accelerated stability programs map viability and potency across transport conditions. The result is confidence that the cell product patients receive mirrors the one produced in the cleanroom.

Operator-driven risk. In many facilities, the weak point is not the science—it’s the operator. Manual open steps, poorly defined ranges, and unrealistic SOPs lead to deviations that compromise product quality. MycoVista eliminates this by designing closed-system trains with operator-holdable settings. Our philosophy is simple: if a parameter cannot be executed reproducibly by trained staff at 2 a.m. on a night shift, it isn’t ready for GMP.

This is why sponsors choose MycoVista. We don’t wait for problems to appear downstream. We build controls upstream, integrate analytics with process, and engineer stability into every operation. That is what modern cell therapy manufacturing demands, and that is what we deliver.

Program spine: QTPP → CQAs → CPPs

Our methodology is structured, transparent, and reproducible. Before a single run is started, we define what success means in measurable terms and then engineer every control to deliver on that definition. This is the spine of every MycoVista program, and it is why our clients’ filings are defensible, their processes scalable, and their therapies consistent.

QTPP (Quality Target Product Profile). We begin by articulating the intended product with the precision of a regulatory reviewer. For an autologous CAR-T, this includes route of administration, viable dose range, presentation format (infusion bag or cryovial), acceptable post-thaw viability, potency thresholds by mechanism-appropriate assay, residual vector limits, sterility, endotoxin, and mycoplasma specifications. For an allogeneic NK therapy, it extends to expansion scale, donor bank comparability, and shelf-life claims supported by stability. The QTPP is not just a concept—it becomes the guiding blueprint for every decision that follows.

CQAs (Critical Quality Attributes). Once the product definition is fixed, we identify the attributes that must be measured to prove we are meeting it. For cell therapy manufacturing, this includes cell viability at harvest and after thaw, transduction efficiency by flow cytometry, expansion kinetics, potency assays (cytotoxicity, cytokine release, or other mechanism-specific tests), residual vector quantitation, and full sterility/endotoxin/mycoplasma panels. For vectors, it includes genome titer, infectivity, and residual host-cell proteins. Each CQA is paired with validated methods, prespecified acceptance windows, and trending strategies that allow us to see drift before it becomes deviation.

CPPs (Critical Process Parameters). Finally, we define the levers that control the CQAs. For cell therapy this means donor material thresholds, MOI and vector dosing strategies, activation and expansion conditions, culture media and feed schedules, cryopreservation recipes, fill–finish pressures, closed-system parameters, and equipment interlocks. For vectors it includes plasmid topology, transfection ratios, production mode, purification gradients, and TFF setpoints. Every CPP is documented in protocols and batch records from the outset, ensuring operators have clear, enforceable instructions.

By linking QTPP → CQA → CPP in this way, MycoVista ensures that our clients’ processes are not only well-designed but also inspection-ready. Regulators don’t want adjectives—they want data tied to controls. Our spine makes that possible. And because it is implemented from the beginning, sponsors save months of remediation and rework when moving from research-grade runs to IND- or BLA-enabling campaigns.

This structured discipline is what elevates MycoVista above other CDMOs. We don’t offer fragmented services—we deliver coherent systems. We don’t retrofit quality—we engineer it from the start. And we don’t leave comparability to chance—we predefine it. This is the foundation of world-class cell therapy manufacturing, and it is why the programs we support succeed at scale and under scrutiny.

Autologous vs. Allogeneic: Design Considerations

We support both therapeutic classes but treat them as distinct, each with its own critical constraints.

• Autologous therapies: Variability between patients is managed by defining acceptance criteria for incoming material, locking operator-holdable controls in activation and expansion, and validating cryopreservation methods to maintain potency across diverse inputs.
• Allogeneic therapies: Scalability is prioritized, with process trains designed to minimize donor-to-donor variability and expansion conditions modeled for reproducibility. Closed-system operations reduce contamination risk and enable comparability at higher batch sizes.

Closed-system manufacturing

Operator reality is the primary driver of quality in cell therapy. Our facilities emphasize closed-system operations—tubing sets, automated expansion units, integrated harvest and fill–finish—where variability and contamination are most easily controlled. Open steps are minimized, interventions are documented and risk-ranked, and comparability bridges are pre-written for any platform changes.

Cryopreservation and storage

The therapy is only as good as the dose that reaches the patient. We treat cryopreservation not as a final step, but as an engineered operation.

• Recipe definition: Empirical testing of cryoprotectants, cooling rates, and thaw methods.
• Hold times: Validation of pre-freeze and post-thaw intervals to ensure stability.
• Presentation: Bags and vials are qualified for freeze–thaw cycles, with container closure integrity testing as required.
• Stability: Real-time and accelerated programs confirm potency, viability, and safety profiles through distribution windows.

Analytics: the questions that matter

Our analytic panel is designed to answer the questions regulators will ask, and developers need to know.

• Cell therapy core panel: Viability, transduction efficiency, expansion kinetics, potency by mechanism-appropriate functional assays, residual vector, sterility, endotoxin, mycoplasma.
• Vector analytics: Genome titer, infectivity, empty/full characterization, potency readouts, and residuals—all aligned with the cell therapy process itself.
• In-process controls: Positioned where they inform decisions, such as MOI effectiveness, expansion curve checkpoints, and cryopreservation feasibility.
• Trending: Control charts for potency, viability, and stability with predefined actions for drift and excursions.

Regulatory and QMS posture

Our regulatory framework is designed to reduce friction at inspection and shorten timelines to approval.

• QbD alignment: Explicit mapping from QTPP to CQA to CPP.
• Digital QMS: Deviation, CAPA, change control, training, investigations—all unified across hubs.
• Comparability: Prespecified protocols for changes in site, scale, or equipment.
• Authoring: CMC sections populated with tables, acceptance criteria, and comparability data—not adjectives.

Facilities and scale

Capabilities are documented transparently, sized to actual program needs.

• Production: Autologous and allogeneic workflows; closed-system platforms validated for clinical and commercial phases.
• Vectors: AAV, LV, and retroviral supply integrated with the cell therapy program.
• Cryopreservation: Controlled-rate freezers, storage facilities qualified for clinical and commercial supply chains.
• Analytics: Flow cytometry, qPCR/ddPCR, potency assays, sterility and mycoplasma testing, stability programs, orthogonal vector characterization.
• Digital systems: eBMR/eBR, ELN, LIMS, CDS validated with audit trails.

Program onboarding

We remove ambiguity up front and structure the program for predictable outcomes.

• Control strategy linking QTPP to CQA to CPP for both cell therapy and vector supply.
• DoE plans covering activation, expansion, transduction, cryopreservation, and release analytics.
• Gantt and risk register with decision gates to IND/IMPD/BLA.
• Written plan returned within 30 days based on sponsor data.

Indicative timelines

Feasibility: Incoming material acceptance, activation screen, expansion test, vector dose optimization, cryopreservation feasibility.
Development: Upstream DoE, transduction and expansion kinetics, potency assay qualification, cryopreservation optimization, stability enrollment.
Engineering: Scale-similar runs, mass balance, stability trending, documentation draft.
Lock: Process description finalized with CPP ranges, validation plans, comparability strategies.

Summary

Cell therapies represent one of the most dynamic and high-value therapeutic classes, but their complexity requires early discipline and integrated execution. At MycoVista, we align autologous and allogeneic workflows with integrated viral vector supply, closed-system manufacturing, and validated cryopreservation. Each step is tied back to the target product profile, with CQAs linked to controlled CPPs and documented for regulators and operators alike. The result is a defensible product, reproducible at scale and resilient through inspection. If your cell therapy program is ready to move forward, share your data and we will return a structured plan with explicit gates and criteria.